AI assistant
Armata Pharmaceuticals, Inc. — Director's Dealing 2006
Nov 9, 2006
34152_dirs_2006-11-09_ea441976-33cd-471d-87fc-6000b457b37f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TARGETED GENETICS CORP /WA/ (TGEN)
CIK: 0000921114
Period of Report: 2006-11-07
Reporting Person: BIOGEN IDEC INC (10% Owner)
Reporting Person: BIOGEN IDEC MA INC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2006-11-07 | Common Stock, $0.01 Par Value | A | 1000000 | — | Acquired | 2170409.5 | Indirect |
Footnotes
F1: Acquired in consideration for the forgiveness of $5.65 million in indebtedness from issuer to Biogen Idec MA Inc. The per share closing price of the issuer's common stock on November 7, 2006 was $2.90.
F2: On May 11, 2006, the common stock of issuer reverse split 1 for 10, resulting in the reporting person's ownership of common stock decreasing by 10,533,682.50 shares.
F3: Shares are owned indirectly by Biogen Idec Inc. and directly by its wholly-owned subsidiary Biogen Idec MA Inc., f/k/a Biogen, Inc.